BCCs treated with shNT CSC-derived EVs expressed higher levels of ALDH1A1, CD133, and NOTCH3 when compared with BCCs treated with BCC-derived EVs. This evidence concerns the gene ALDH1A1 and skin basal cell carcinoma.